

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-548
C# M#

#18

HAYNES et al

Group Art Unit: 1648

Serial No. 09/775,805

Examiner: Stucker, J.

Filed: February 5, 2001

Date: July 21, 2003

Title: HUMAN IMMUNODEFICIENCY VIRUS VACCINE

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
03 JUL 21 2003 6:45

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

 Correspondence Address Indication Form Attached.**Fees are attached as calculated below:**

Total effective claims after amendment previously paid for	20	(at least 20)	=	0	minus highest number		\$	0.00
Independent claims after amendment previously paid for	3	(at least 3)	=	0	minus highest number		\$	0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)							\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months)							\$	0.00
Terminal disclaimer enclosed, add \$ 110.00							\$	0.00
<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00)							\$	0.00
<input type="checkbox"/> Please enter the previously unentered , filed								
<input type="checkbox"/> Submission attached								
							Subtotal	\$ 0.00
If "small entity," then enter half (1/2) of subtotal and subtract							-\$	0.00
<input type="checkbox"/> Applicant claims "small entity" status. <input type="checkbox"/> Statement filed herewith								
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)							\$	0.00
Assignment Recording Fee (\$40.00)							\$	0.00
Other:								0.00
							TOTAL FEE ENCLOSED	\$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat
07/15/2003 NVILLARI 0000003 09775805

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

03 JUL 21 2003
PTO-1449
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In re Patent Application of

HAYNES et al

Atty. Ref.: 1579-548

Serial No. 09/775,805

Group: 1648

Filed: February 5, 2001

Examiner: Stucker, J.

For: HUMAN IMMUNODEFICIENCY VIRUS VACCINE

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 21, 2003

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C

2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00

3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and

a) The required Statement made in item 8 below; or

b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and

b) The required Statement is stated in item 8 below.

8. Statement under 37 CFR 1.97(e)

a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. While no further fee is believed to be required, if the Office takes a different view, authorization is hereby given to charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

The Examiner's attention is directed to the following co-pending cases: U.S. Patent Application No. 10/373,592, filed February 26, 2003, U.S. Patent Application No. 10/431,596, filed May 8, 2003, U.S Patent Application No. 09/956,940, filed September 21, 2001, U.S. Provisional Application No. 60/471,327, filed May 19, 2003, U.S. Provisional Application No. 60/471,327, filed May 19, 2003 and U.S. Provisional Application No. 60/397,605, filed July 23, 2002 (copies of which are attached). The Examiner's attention is also directed to co-pending cases U.S. Patent Application No. 08/599,266, filed February 9, 1996 which corresponds to WO 97/14436 and U.S. Patent Application No. 09/960,717, filed September 24, 2001 which corresponds to WO 02/02419 (copies of these published PCT applications were provided with the Information Disclosure Statement filed January 24, 2003).

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100